" class="no-js "lang="en-US"> Inszone Insurance Services Completes Acquisition of Kirsch Insurance Group - Medtech Alert
Thursday, May 23, 2024

Inszone Insurance Services Completes Acquisition of Kirsch Insurance Group

Inszone Insurance Services, a rapidly growing, national provider of benefits, personal and commercial lines insurance, has announced the acquisition of Kirsch Insurance Group.

Marlin Kirsch founded Kirsch Insurance Group in 2004. A Denver-based brokerage that specializes in Medicare Health Plans, Kirsch Insurance has focused on helping their clients in finding the best program for their specific needs. Their comprehensive grasp of all Medicare Plans and Options has helped them to assist clients in being better prepared for the future.

“After years in the company, we’ve acquired a reputation for educating consumers in an easy-to-understand manner, so they can readily grasp the frequently perplexing concepts of the ‘Medicare Maze’,” says Marlin Kirsch, the agency’s prior owner.

The service that Kirsch Insurance clients are accustomed to will continue uninterrupted under the Inszone Insurance brand.

Chris Walters, CEO of Inszone Insurance, said, “Colorado has been a great source of growth for us; the acquisition of Kirsch Insurance is another milestone in our expansion in the state as we move toward our goal of establishing Inszone as Colorado’s go-to insurance agency.”

The acquisition of Kirsch Insurance is part of the continued expansion and growth by Inszone Insurance and becomes the 9th acquisition so far in the Colorado area. Inszone Insurance is expected to announce several acquisitions as well as new locations in the upcoming months.

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more